Caris Life Sciences (NASDAQ:CAI) Given New $36.00 Price Target at Citigroup

Caris Life Sciences (NASDAQ:CAI) had its target price increased by Citigroup from $28.00 to $36.00 in a research note published on Friday,Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other analysts have also commented on the company. Wall Street Zen raised Caris Life Sciences from a “sell” rating to a “hold” rating in a research note on Sunday, August 16th. JPMorgan Chase & Co. boosted their target price on shares of Caris Life Sciences from $25.00 to $35.00 and gave the company an “overweight” rating in a research note on Wednesday, October 14th. Weiss Ratings lowered shares of Caris Life Sciences from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, October 2nd. UBS Group set a $38.00 target price on shares of Caris Life Sciences in a report on Thursday. Finally, Canaccord Genuity Group raised their price target on shares of Caris Life Sciences from $22.00 to $30.00 and gave the stock a “hold” rating in a research note on Monday, October 19th. Eight analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $30.82.

Caris Life Sciences Price Performance

CAI traded down $0.80 during midday trading on Friday, reaching $25.23. 10,287,488 shares of the company’s stock were exchanged, compared to its average volume of 3,532,322. Caris Life Sciences has a 1-year low of $14.19 and a 1-year high of $36.50. The stock has a market capitalization of $7.13 billion, a PE ratio of 76.45 and a beta of 0.71. The company has a debt-to-equity ratio of 0.66, a current ratio of 5.53 and a quick ratio of 4.88. The business’s 50-day moving average price is $29.48 and its 200 day moving average price is $21.74.

Caris Life Sciences (NASDAQ:CAI) last released its quarterly earnings results on Wednesday, November 4th. The company reported $0.05 EPS for the quarter, beating the consensus estimate of $0.03 by $0.02. Caris Life Sciences had a net margin of 10.62% and a return on equity of 18.77%. The business had revenue of $275.36 million for the quarter. During the same quarter in the prior year, the company earned $0.08 earnings per share. The firm’s revenue for the quarter was up 27.0% compared to the same quarter last year. As a group, equities analysts anticipate that Caris Life Sciences will post 0.13 EPS for the current fiscal year.

Insiders Place Their Bets

In other Caris Life Sciences news, President David Spetzler sold 119,212 shares of Caris Life Sciences stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $24.76, for a total value of $2,951,689.12. Following the completion of the sale, the president owned 1,182,871 shares in the company, valued at $29,287,885.96. The trade was a 9.16% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Brian Brille sold 400,000 shares of the company’s stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $30.33, for a total transaction of $12,132,000.00. Following the transaction, the insider directly owned 230,303 shares of the company’s stock, valued at approximately $6,985,089.99. This represents a 63.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 1,004,712 shares of company stock valued at $27,205,419. Insiders own 50.00% of the company’s stock.

Hedge Funds Weigh In On Caris Life Sciences

Several institutional investors and hedge funds have recently bought and sold shares of CAI. Braidwell LP boosted its holdings in shares of Caris Life Sciences by 3.1% in the 2nd quarter. Braidwell LP now owns 8,256,032 shares of the company’s stock valued at $147,122,000 after purchasing an additional 246,585 shares during the last quarter. PointState Capital LP acquired a new position in Caris Life Sciences in the second quarter valued at $121,690,000. BlackRock Inc. purchased a new stake in Caris Life Sciences during the second quarter valued at about $98,666,000. Canada Pension Plan Investment Board purchased a new stake in Caris Life Sciences during the second quarter valued at about $24,502,000. Finally, Amundi increased its stake in Caris Life Sciences by 5,709.5% during the second quarter. Amundi now owns 1,218,364 shares of the company’s stock worth $21,711,000 after acquiring an additional 1,197,392 shares during the last quarter.

More Caris Life Sciences News

Here are the key news stories impacting Caris Life Sciences this week:

• Positive Sentiment: Citigroup raised its price target to $36 from $28 and maintained a Buy rating. BTIG Research also reiterated Buy, with a $38 target. Citigroup rating BTIG rating
• Positive Sentiment: Goldman Sachs stuck with its Buy rating, adding to the favorable analyst sentiment around CAI. Goldman Sachs rating
• Positive Sentiment: Third-quarter revenue grew 27% year over year to $275.36 million, while EPS of $0.05 beat the $0.03 consensus. Caris also raised its fiscal 2026 outlook, supporting expectations for continued growth. Q3 results and outlook
• Negative Sentiment: Despite the revenue growth and EPS beat, net income declined 37% year over year, with higher expenses weighing on profitability. EPS was also below the $0.08 reported a year earlier, a potential concern for investors focused on margins. Profit decline report

About Caris Life Sciences

Caris Life Sciences is a biotechnology and precision-medicine company that uses molecular profiling and artificial intelligence to support cancer diagnosis, treatment selection and drug development. The company analyzes tumor and blood samples to identify genomic, molecular and immune characteristics that may help physicians better understand a patient’s disease and select targeted therapies.

Its offerings include comprehensive tumor profiling, liquid-biopsy testing and data-driven clinical decision-support tools.